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Endothelium, which is a dynamic organ, forms a structural barrier between the vas-
cular space and the tissues. Endothelial cells have contact with numerous smooth mus-
cle cells. Many factors such as LDL (low-density lipoproteins), free radicals, infectious
microorganisms, shear stress, hypertension, toxins after smoking and/or others may lead
to endothelial dysfunction, which is characterized by decreased nitric oxide synthesis.
Disturbance in endothelial function is implicated in several diseases, including athero-
sclerosis, hypertension, inflammatory diseases and cancer metastasis (1–4). Destruction
of endothelium by the above-mentioned agents can lead to the release of cytokines and
growth factors such as basic fibroblast growth factor (bFGF), which has mitogenic effects
on smooth muscle cells (5). The inflammatory process is also responsible for endothelial
dysfunction and generation of some growth factors and plays an important role in the
progression of atherosclerotic plaque formation. Hypoxia stimulates vascular endothe-
lial growth factor (VEGF) secretion, which is responsible for the formation of new blood
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Diclofenac belongs to non-steroidal anti-inflammatory
drugs (NSAIDs) and non-selective COX inhibitors. The
aim of this study was to examine the effect of diclofenac
on endothelial cell proliferation under the influence of
hypoxia or inflammatory conditions. Another goal was
to check whether diclofenac modulates the secretion of
angiogenic factors such as VEGF and bFGF in human
microvascular endothelial cells (HMEC-1) in the presen-
ce of CoCl2 or lipopolysaccharide (LPS), which could in-
fluence the endothelial cells in an autocrine manner or
other cells in a paracrine manner. HMEC-1 cells were tre-
ated with 0.1 and 0.3 mmol L–1 diclofenac in the presence
of 100 µg mL–1 LPS or 200 µmol L–1 CoCl2. Diclofenac
decreased cell viability under hypoxia and inflammatory
conditions. The stimulation of bFGF secretion by LPS in
microvascular endothelial cells (HMEC-1 cell) was attenu-
ated by diclofenac. Diclofenac increased the secretion of
VEGF induced by LPS and hypoxia.
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vessels and solid tumor progression and metastasis. However, neovascularization need
not always be associated with pathological processes. An example of positive impact may
be effects on the cardiovascular system in the case of ischemic heart disease (1–5).
Diclofenac, a non-selective COX inhibitor, is often used in inflammatory diseases
such as rheumatoid arthritis. However, there is no explicit information about the effects
of non-steroidal anti-inflammatory drugs (NSAIDs) on the secretion of angiogenic growth
factors (VEGF, bFGF) by normal endothelial cells. Many studies have reported antian-
giogenic effects of cyclooxygenase COX-2 inhibitors on cancer cells (6). Among traditio-
nal NSAIDs, diclofenac is the strongest inhibitor of COX-2. This behavior is responsible
for significant cardiovascular toxicity resulting from the use of diclofenac. Cardiovascu-
lar toxicity is connected with two major mechanisms. Firstly, the main mechanism is the
inhibition of prostaglandin generation in the endothelium, which is associated with in-
creased risk of atherothrombotic vascular events. The second mechanism is also medi-
ated by prostaglandin inhibition, which can induce sodium and water retention. This effect
leads to an increase in blood pressure (7). Diclofenac, more often than other traditional
NSAIDs, leads to myocardial infarction and has the highest risk of cardiovascular mor-
bidity and mortality, including fatal or nonfatal stroke and coronary death (7). Meta-
-analysis published in the Lancet in 2013 showed that the cardiovascular risk of diclo-
fenac is similar to rofecoxib (selective COX-2 inhibitor) effect (8).
In turn, in ischemic heart disease, collateral vessel formation plays an important role in
protecting the myocardium from ischemia. Recent studies show that f.e. bFGF can be
responsible for myocardial regeneration and thereby improvement of cardiac function (9,
10). Thus, it seems important to investigate the effect of diclofenac on growth factors (VEGF,
bFGF) and to identify additional factors relevant to the cardiovascular effects of NSAIDs.
Therefore, in this study it was decided to examine the effect of the non-selective COX
inhibitor – diclofenac on endothelial cell survival under the influence of hypoxia or
inflammatory conditions. The other aim was to check whether diclofenac modulates the
secretion of angiogenic factors such as VEGF and bFGF in human microvascular endothelial
cells (HMEC-1) in the presence of CoCl2 or bacterial lipopolysaccharide (LPS), which could
influence endothelial cells in an autocrine manner or other cells in a paracrine manner.
EXPERIMENTAL
Chemicals
The following substances were used: MCDB 131 medium, fetal bovine serum, peni-
cillin-streptomycin solution (5,000 units mL–1 penicillin and 5,000 µg mL–1 streptomycin
sulphate in normal saline), phosphate buffered saline (PBS, pH 7.4) and trypsine-EDTA
(0.25 % trypsin, 1 mmol L–1 Na4-EDTA). They were purchased from Invitrogen (USA).
Cobalt chloride, diclofenac, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromi-
de (MTT), human epidermal growth factor (EGF), lipopolysaccharides from Salmonella
enteritidis (LPS) and hydrocortisone were purchased from Sigma Chemical Co. (USA).
Cell culture
HMEC-1 (human microvascular endothelial cells) were purchased from ATCC (cells
deposited by the Centers for Disease Control, Atlanta, USA). The cells were used betwe-
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en passages 10–31 and cultured in 25-mL flasks in medium composed of MCDB 131 sup-
plemented with 10 % fetal bovine serum, 10 ng mL–1 epidermal growth factor, 1 µg mL–1
hydrocortisone and penicillin-streptomycin solution, in a humidified atmosphere of 95 %
and 5 % CO2 at 37 °C. Cells were harvested every third day in a trypsin-EDTA solution
(0.25 % trypsin, 1 mmol L–1 EDTA).
MTT conversion
HMEC-1 cell proliferation was measured using the MTT conversion method. Cells
were seeded (50 000 cells per well) into 96-well plates. The treated cells were incubated
for 24 h. After incubation, 50 µL of MTT (1 mg mL–1) was added and the plates were
incubated at 37 °C for 4 h. At the end of the experiment, cells were exposed to 100 µL
dimethyl sulphoxide, which enabled release of the blue reaction product – formazan.
Absorbance at 570 nm was read on a microplate reader and results were expressed as the
percentage of absorbance measured in control cells.
ELISA assays
VEGF and bFGF concentrations in cell culture media were determined by commer-
cially available ELISA kits according to the vendor’s protocols (R&D System, UK).
Data analysis
All data are expressed as the mean ± SEM values. For statistical evaluation of the
results, an analysis of variance (ANOVA) was performed, followed by a post-hoc Student-
-Newman-Keuls test.
RESULTS AND DISCUSSION
Endothelial cells produce prostaglandins from arachidonic acid in physiological
processes responsible for vasodilatation and anti-aggregation and in pathophysiological
processes such as inflammation, arthritis and cancer (11, 12). Diclofenac, as a non-
-selective COX inhibitor, inhibits cyclooxygenase-1 and 2; it therefore blocks the forma-
tion of prostaglandins (PGs).
Effect of diclofenac on cell viability in the presence of cobalt chloride or bacterial
LPS in HMEC-1
In these studies, diclofenac, used at a concentration of 0.01–1.0 mmol L–1, inhibited
HMEC-1 cell viability (Fig. 1a). The range of concentrations inducing inhibition of cell
survival up to 50 % (IC50) was estimated from the concentration-response curve obtain-
ed for endothelial cells. IC50 for diclofenac was 0.1 mmol L–1. A statistically significant
decrease of cell viability was observed at diclofenac concentrations of 0.1, 0.3 and 1.0
mmol L–1. These findings are consistent with our previous results (unpublished) and
those of other authors who found that sulindac (13), aspirin (14) (non-selective COX in-
hibitors) and celecoxibe (selective COX-2 inhibitor) (15) are related to antiproliferative
and proapoptotic activities. Flis et al. (13) concluded that antiproliferative effect of sulin-
dac sulfide is due to COX-dependent and COX-independent mechanisms.
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In a subsequent set of experiments, we studied the influence of diclofenac at a con-
centration of 0.01–0.3 mmol L–1 on the human microvascular cell viability under hypo-
xia (CoCl2, 200 µmol L–1) and inflammatory (LPS, 100 µg mL–1) conditions (Fig. 1b). LPS
deriving from the Salmonella enteritidis cell wall induces inflammation in endothelial
cells as well as COX-2 and prostaglandins (PGE2), which are responsible for prolifera-
tion of endothelial cells (14, 16). As shown in Fig. 1b, LPS at 100 µg mL–1 stimulated
proliferation of HMEC-1 cells by 33 % (p < 0.05). Diclofenac, as a non-selective COX inhi-
bitor, used at concentrations from 0.01 to 0.3 mmol L–1 inhibited the proliferative effect
of LPS at 100 µg mL–1 by 28, 44 and 46 %, respectively, in comparison with the control
and by 53, 64 and 64.5 %, respectively, in comparison with LPS.
Previous reports indicated that LPS was responsible for the induction of cyclooxy-
genase-2 in bovine aortic endothelial cells (BAEC) and intensified cell proliferation (17).
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Fig. 1. Effects of diclofenac on viability of cultured HMEC-1 cells: a) diclofenac (0.01–1.0 mmol L–1);
b) diclofenac (0.01–0.3 mmol L–1) in the presence of CoCl2 (200 µmol L
–1) or LPS (100 µg mL–1). Bars
represent means ± SEM of 4–15 experiments. *p < 0.05 vs. control; # p < 0.05 vs. CoCl2 (200 µmol L
–1);
§ p < 0.05 vs. LPS (100 µg mL–1). Abbreviations: CoCl2 200 – CoCl2 200 µmol L
–1; LPS 100 – LPS 100 µg
mL–1; Diclo 0.01 – diclofenac 0.01 mmol L–1; Diclo 100 – diclofenac 0.1 mmol L–1; Diclo 0.3 – dic-
lofenac 0.3 mmol L–1.
a)
b)
Thus, non-selective COX inhibitors (diclofenac), inhibiting prostaglandin synthesis,
possess antiproliferative activity (13–15). However, it is emphasized in the literature that
COX inhibitors may also enhance apoptosis regardless of the effect on prostaglandin (13,
15). In the present study, diclofenac (non-selective COX-2 inhibitor) reduced the pro-
liferative effect of LPS in dose-dependent manner and in a statistically significant manner.
In contrast, cobalt chloride (CoCl2), a hypoxia mimicking agent, decreased endothe-
lial cell survival in a statistically significant manner (Fig. 1b). Diclofenac, at concentra-
tions of 0.01 and 0.1 mmol L–1, did not change cell viability weakened by CoCl2 while
increased inhibition of cell viability of HMEC-1 cells at 0.3 mmol L–1 was observed. The
strongest effect of diclofenac in the presence of LPS and CoCl2 was observed at a con-
centration of 0.3 mmol L–1. NSAIDs can augment inhibition of the survival cell effect of
hypoxia and decrease the proliferative effect of inflammation.
Effect of diclofenac on bFGF secretion evoked by bacterial LPS in HMEC-1
Antiproliferative and antiangiogenic effect of diclofenac may be associated with the
decrease of bFGF after treating HMEC-1 with diclofenac under inflammatory conditions
(Fig. 2). LPS induced secretion of bFGF in HMEC-1 cells by 107 % in a statistically sig-
nificant manner. Diclofenac at concentrations of 0.1 and 0.3 mmol L–1 did not influence
the secretion of bFGF in HMEC-1 cells. In the presence of LPS, diclofenac inhibited for-
mation of bFGF stronger at higher concentration (0.3 mmol L–1) than at concentration of
0.1 mmol L–1. This observation was statistically significant (p < 0.05). Other reports
showed that under inflammatory conditions endothelium may secrete bFGF, which may
stimulate proliferation of smooth muscle cells (5, 12). This study showed that diclofenac
may inhibit secretion of bFGF by endothelial cells and the proliferative effect of bFGF on
smooth muscle cells. Effect of diclofenac on bFGF under inflammation conditions is di-
rectly proportional to the concentration.
Effect of diclofenac on VEGF secretion evoked by cobalt chloride or bacterial LPS in
HMEC-1
According to the previous studies of Namiecinska et al. (18) and Loboda et al. (19,
20), expression of VEGF in human microvascular endothelial cells (HMEC-1 cells), can
be induced by both hypoxia (1 and 3 % O2) and cobalt chloride, a hypoxia mimicking
agent (21) and LPS (22). Similarly, in the present work, the level of VEGF after 24-hour
incubation with CoCl2 at 200 µmol L–1 was 4.7-fold (p < 0.05) higher than that of the con-
trol (Fig. 3). At a concentration of 100 µg ml–1, LPS stimulated the generation of VEGF by
101 % in comparison with the control (p < 0.05). Increase of VEGF level evoked by hy-
poxia was 2.35-fold higher than under the influence of inflammation in HMEC-1.
Incubation of HMEC-1 cells with diclofenac, at 0.1 and 0.3 mmol L–1, increased the
level of VEGF by 152 and 166 %, respectively, in comparison with the control. In the sub-
sequent set of experiments, the influence of diclofenac (0.1 and 0.3 mmol L–1) on the
VEGF secretion under hypoxia and inflammatory conditions was studied. 24-hour incu-
bation with diclofenac (0.1 and 0.3 mmol L–1) under hypoxia conditions further inten-
sified the production of VEGF by 10.5 and 16 %, respectively (p < 0.05). Diclofenac (0.1
and 0.3 mmol L–1) when applied with LPS potentiated the secretion of VEGF by 125 and
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60 %, respectively (p < 0.05), in comparison with LPS alone. In the presence of LPS, diclo-
fenac at a concentration of 0.3 mmol L–1 stimulated secretion of VEGF to a lower extent
than 0.1 mmol L–1 diclofenac (by 29 %). This observation was statistically significant. In
summary, diclofenac simulated secretion of VEGF in a manner opposite to the dose, the
higher dose of diclofenac (0.3 mmol L–1) induced VEGF secretion less than the lower
dose (0.1 mmol L–1) under inflammatory conditions.
CONCLUSIONS
The obtained findings demonstrate that LPS could induce HMEC-1 proliferation
through a COX-signaling mechanism. The classical NSAID – diclofenac could inhibit this
step of HMEC-1 proliferation. This non-selective COX inhibitor potentiated the secretion
of VEGF under hypoxia and inflammatory conditions. Diclofenac inhibits LPS-induced
136
A. Wiktorowska-Owczarek: The effect of diclofenac on proliferation and production of growth factors by endothelial cells (HMEC-1)
under hypoxia and inflammatory conditions, Acta Pharm. 64 (2014) 131–138.
Fig. 2. Effects of diclofenac (0.1 and 0.3 mmol L–1) on bFGF levels in HMEC-1 cells in the presence of
LPS (100 µg mL–1). Bars represent means ± SEM of 3–5 experiments. * p < 0.05 vs. control; # p < 0.05
vs. LPS (100 µg mL–1); § p < 0.05 vs. LPS (100 µg mL–1) and diclofenac (0.1 mmol L–1). Abbreviations:
LPS 100 – LPS 100 µg mL–1; Diclo 0.1 – diclofenac 0.1 mmol L–1; Diclo 0.3 – diclofenac 0.3 mmol L–1.
Fig. 3. Effects of diclofenac (0.1 and 0.3 mmol L–1) on VEGF levels in HMEC-1 cells in the presence
of CoCl2 (200 µmol L
–1) or LPS (100 µg mL–1). Bars represent mean ± SEM of 3–5 experiments. * p < 0.05
vs. control; # p < 0.05 vs. CoCl2 (200 µmol L
–1); § p < 0.05 vs. LPS (100 µg mL–1); $ p < 0.05 vs. LPS (100
µg mL–1) and diclofenac (0.1 mmol L–1). Abbreviations: CoCl2 200 – CoCl2 200 µmol L
–1; LPS 100 –
LPS 100 µg mL–1; Diclo 0.1 – diclofenac 0.1 mmol L–1; Diclo 0.3 – diclofenac 0.3 mmol L–1.
secretion of bFGF in a dose-dependence manner. The observed inhibition of bFGF se-
cretion by diclofenac under inflammatory conditions can play an important role in car-
diac function deterioration in coronary diseases. Further studies are required to deter-
mine the mechanism of VEGF and bFGF generation under inflammatory conditions and
in the presence of diclofenac.
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